CVM

CEL-SCI is a clinical-stage biologic with essentially zero product revenue (the last tagged figure is a stale $264K from FY2014) and a $539M accumulated deficit — three-plus decades of losses with nothing commercialized. Its lead asset, Multikine, began Phase III in December 2010, reached its primary endpoint in April 2020, was unblinded in June 2021, and per the MD&A the company still 'plans to conduct a confirmatory registration study' before it can even file for U.S. marketing authorization. That means the payoff is years away, gated on more capital and more trials, with no assurance of approval. Management itself states it 'cannot predict when it will be able to generate any revenue' and 'will likely continue to generate net operating losses.'

The balance sheet cannot fund that path. FY2025 operating cash flow was -$17.1M against just $11.0M of cash — under a year of runway — and the company openly finances itself through 'issuance of equity securities, convertible notes, loans and certain research grants.' The 83.2% collapse in share count (to 8.41M) is a reverse split, and the $-6.27 diluted EPS reflects that engineering, not any improvement in the business; the $9.59M market cap and 36.3x P/S built on non-recurring revenue are meaningless valuation artifacts. Cash rose 131% only because they raised it, and shareholders bear the dilution. This is a going-concern-adjacent capital treadmill.